Company News 30 Apr 2026 Orthocell achieves first Remplir™ sales in US$75 million Canadian Market Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in… Orthocell
Company News 28 Apr 2026 Remplir™ RWE study delivers 90% success rate Orthocell has announced compelling new data from its ongoing Remplir™ Real World Evidence (RWE) study, demonstrating strong and consistent clinical outcomes across a broad… Orthocell
Company News 20 Apr 2026 Orthocell reports continued growth and strong US momentum in March 2026 quarter Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial… Orthocell
Company News 17 Apr 2026 First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans… Orthocell
Company News 15 Apr 2026 Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence and Veterans Affairs (VA) hospital networks, marking a significant… Orthocell
Video 09 Apr 2026 Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US… Orthocell
Company News, Video 01 Apr 2026 Investor Presentations | March 2026 Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on… Orthocell
Company News 25 Mar 2026 The Armchair Analyst | What makes a surgeon adopt a product? Surgeon adoption is a key factor in the commercialisation of medical technologies. But what influences whether a surgeon chooses to adopt… Orthocell
Company News 18 Mar 2026 Remplir™ Used in 23 Surgeries on Injured Soldiers in Ukraine Orthocell has announced that its Remplir™ nerve repair device has been used in 23 surgical procedures on injured soldiers in Ukraine. Orthocell
Company News, Video 02 Feb 2026 February 2026 Orthocell Investor Webinar Replay In this webinar, Orthocell Chair, John Van Der Wielen, CEO and MD, Paul Anderson, and Independent Director, Dr Ravi Thadani provide an important operational update… Orthocell
